Company Overview and News
MONTRÉAL, QUÉBEC--(Marketwired - March 2, 2018) - Cogeco Inc. (TSX:CGO) and Cogeco Communications Inc. (TSX:CCA) plan to release their financial results for the second quarter of fiscal 2018, ended February 28, 2018, on Thursday, April 12, 2018, after market closing.
MONTRÉAL, QUÉBEC--(Marketwired - Feb. 6, 2018) - Cogeco Inc. (TSX:CGO) ("Cogeco" or the "Corporation") announced today that Gestion Audem Inc. has entered into an agreement for the sale of 288,180 subordinate voting shares on a private placement basis. The transaction does not alter the control of Cogeco since, upon completion of this transaction, Gestion Audem will retain control and ownership over 1,809,660 multiple voting shares and 77,540 subordinate voting shares of Cogeco, representing in aggregate 71.
Flexible services optimize customer's Azure investments, handle the day-to-day management of the platform with dedicated, secure, low latency connection to Azure
MONTRÉAL, QUÉBEC--(Marketwired - Jan. 12, 2018) - Cogeco Communications Inc. ("Cogeco Communications") (TSX:CCA) is pleased to announce that each of the nominees as directors for Cogeco Communications listed in the Corporation's information circular dated November 17, 2017 was elected as director of Cogeco Communications during its annual shareholders' meeting held on January 11, 2018 in Montréal, Québec (the "Meeting").
MONTRÉAL, QUÉBEC--(Marketwired - Jan. 12, 2018) - Cogeco Inc. ("Cogeco") (TSX:CGO) is pleased to announce that each of the nominees as directors for Cogeco listed in the Corporation's information circular dated November 17, 2017 was elected as director of Cogeco during its annual shareholders' meeting held on January 11, 2018 in Montréal, Québec (the "Meeting").
MONTRÉAL, QUÉBEC--(Marketwired - Jan. 11, 2018) - Cogeco Inc. (TSX:CGO) and Cogeco Communications Inc. (TSX:CCA) announced today the publication of their fourth Corporate Social Responsibility (CSR) Report. This report, issued once every two years, is produced according to the international Global Reporting Initiative (GRI) guidelines. It communicates the company's initiatives, its targets and commitments, as well as the most material issues linked to its environmental, social and governance (ESG) performance.
MONTRÉAL, QUÉBEC--(Marketwired - Jan. 9, 2018) - Representatives of the media are invited to a press briefing just ahead of the Annual Shareholders' Meetings for Cogeco Inc. (TSX:CGO) and Cogeco Communications Inc. (TSX:CCA). The companies' President and Chief Executive Officer, Louis Audet, will be available to speak about both companies' results for fiscal year 2017 as well as for the first quarter of fiscal year 2018.
LONDON, UK / ACCESSWIRE / January 05, 2018 / Active-Investors free stock reports for this morning include these Toronto Exchanges' equities from the Communication Services industry: NeuLion, Quebecor, Cogeco Communications, and NTG Clarity Networks. Access our complimentary up-to-the-minute research reports by becoming an online member now:
MONTRÉAL, QUÉBEC and QUINCY, MASSACHUSETTS--(Marketwired - Jan. 4, 2018) - Cogeco Communications Inc. (TSX:CCA) announced today that its subsidiary Atlantic Broadband has completed the acquisition of cable systems owned by Harron Communications, L.P. and operating under the MetroCast brand name ("MetroCast").
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...
2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...